[Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
暂无分享,去创建一个
[1] Y. Yamamura,et al. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms , 1973, Neurology.
[2] P. Ballard,et al. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983, The New England journal of medicine.
[3] Langston Jw,et al. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .
[4] Y. Mizuno,et al. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.
[5] T. Nagatsu. [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.
[6] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[7] J. Langston,et al. Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.
[8] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[9] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[10] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[11] M. Goedert,et al. Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.
[12] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[13] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[14] T. Kondo,et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q , 1998, Neurology.
[15] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[16] M. Citron,et al. Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.
[17] M. Vila,et al. α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.
[18] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[19] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[20] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[21] Shinsei Minoshima,et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.
[22] D. Sulzer,et al. Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.
[23] M. Schwarzschild,et al. Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[24] Glenda M. Halliday,et al. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .
[25] D. Hernandez,et al. Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.
[26] G. Halliday,et al. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. , 2001, Annals of neurology.
[27] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[28] M. Zigmond,et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[29] Robert Burke,et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] Miguel A Hernán,et al. A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.
[31] M. Zigmond,et al. A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.
[32] J. C. Greene,et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] M. Vila,et al. The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model , 2003 .
[34] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[35] M. Vila,et al. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. , 2003, Annals of the New York Academy of Sciences.
[36] Leonidas Stefanis,et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.
[37] S. Lipton,et al. Molecular pathways to neurodegeneration , 2004, Nature Medicine.
[38] N. Hattori,et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations , 2004, Neurology.
[39] R. Edwards,et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[40] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[41] Philippe Amouyel,et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.
[42] A Dürr,et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.
[43] Robert Edwards,et al. Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.
[44] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[45] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[46] D. Price,et al. Axonal transport of human α‐synuclein slows with aging but is not affected by familial Parkinson's disease‐linked mutations , 2003, Journal of neurochemistry.
[47] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[48] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[49] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[50] A Dürr,et al. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[51] N. Hattori,et al. A Combinatorial Code for the Interaction of α-Synuclein with Membranes* , 2005, Journal of Biological Chemistry.
[52] R. Hilker,et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers , 2005, Annals of neurology.
[53] N. Hattori,et al. A combinatorial code for the interaction of alpha-synuclein with membranes. , 2005, The Journal of biological chemistry.
[54] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[55] Andrew B West,et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[56] P. Axelsen,et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. , 2005, The Journal of biological chemistry.
[57] Paul H. Axelsen,et al. The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.
[58] Changan Jiang,et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.
[59] I. Ferrer,et al. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. , 2006, Neurobiology of aging.
[60] Sunhong Kim,et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.
[61] S. Lindquist,et al. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.
[62] A. Singleton,et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. , 2006, Annals of neurology.
[63] A. Singleton,et al. Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease , 2006 .
[64] C. Ross,et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.
[65] Christine Klein,et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.
[66] J. Trojanowski,et al. Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery , 2006, Neuron.
[67] T. Meitinger,et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.
[68] P. Pollak,et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.
[69] B. Oostra,et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan , 2006, Neurogenetics.
[70] Matthew J. Farrer,et al. LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.
[71] H. Qing,et al. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation , 2007, Acta Neuropathologica.
[72] N. Hattori,et al. Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population , 2007, Neuroreport.
[73] H. Braak,et al. Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.
[74] K. Lim,et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.
[75] Salil K. Das,et al. Cigarette smoke and dopaminergic system , 2007, Journal of biochemical and molecular toxicology.
[76] H. Sershen,et al. Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein , 2008, Neurochemical Research.
[77] N. Hattori,et al. Sept4, a Component of Presynaptic Scaffold and Lewy Bodies, Is Required for the Suppression of α-Synuclein Neurotoxicity , 2007, Neuron.
[78] N. Hattori,et al. Leucine-rich repeat kinase 2 associates with lipid rafts. , 2007, Human molecular genetics.
[79] Jun Guo,et al. Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells , 2007, Cellular and Molecular Neurobiology.
[80] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[81] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[82] Hansong Deng,et al. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila , 2008, Proceedings of the National Academy of Sciences.
[83] B. Jeon,et al. α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.
[84] N. Zhang,et al. alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. , 2008, The Journal of biological chemistry.
[85] S. Yazawa,et al. Familial Parkinsonism with digenic parkin and PINK1 mutations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[86] Ted M. Dawson,et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy , 2009, Proceedings of the National Academy of Sciences.
[87] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[88] N. Hattori,et al. Pathogenesis of familial Parkinson’s disease: new insights based on monogenic forms of Parkinson’s disease , 2009, Journal of neurochemistry.
[89] E. Waxman,et al. Clinical and pathological characteristics of patients with Leucine‐rich repeat kinase‐2 mutations , 2009, Movement disorders : official journal of the Movement Disorder Society.
[90] Beate Ritz,et al. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. , 2009, American journal of epidemiology.
[91] Brian Spencer,et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.
[92] Jie Shen,et al. Absence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice , 2009, Journal of neurochemistry.
[93] N. Hattori,et al. Parkin stabilizes PINK1 through direct interaction. , 2009, Biochemical and biophysical research communications.
[94] Atsushi Tanaka,et al. PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.
[95] N. Sokol,et al. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression , 2010, Nature.
[96] Christian Hansen,et al. Are synucleinopathies prion-like disorders? , 2010, The Lancet Neurology.
[97] N. Hattori,et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy , 2010, The Journal of cell biology.
[98] Yusuke Nakamura,et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.
[99] Fabienne C. Fiesel,et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 , 2010, Nature Cell Biology.
[100] P. Nicotera,et al. Paraquat and Parkinson's disease , 2010, Cell Death and Differentiation.
[101] N. Hattori,et al. PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy , 2010, FEBS letters.
[102] D. Berwick,et al. LRRK2 signaling pathways: the key to unlocking neurodegeneration? , 2011, Trends in cell biology.